Verrica Pharmaceuticals Inc. financial data

Symbol
VRCA on Nasdaq
Industry
Pharmaceutical Preparations
Location
10 North High Street, Suite 200, West Chester, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 277 % -74.4%
Quick Ratio 11.4 %
Debt-to-equity -993 % -2968%
Return On Equity 1.3K %
Return On Assets -146 % -106%
Operating Margin -843 % +44.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.6M shares +8.41%
Common Stock, Shares, Outstanding 45.6M shares +8.41%
Entity Public Float 152M USD +384%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 46.8M shares +1.59%
Weighted Average Number of Shares Outstanding, Diluted 46.8M shares +1.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.21M USD +187%
Cost of Revenue 400K USD +33.3%
Research and Development Expense 17.2M USD +2.62%
General and Administrative Expense 17.4M USD -25.8%
Operating Income (Loss) -77.6M USD -59%
Nonoperating Income (Expense) -7.35M USD -1507%
Net Income (Loss) Attributable to Parent -85M USD -75.9%
Earnings Per Share, Basic -1.85 USD/shares -90.7%
Earnings Per Share, Diluted -1.85 USD/shares -90.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23M USD -72.8%
Cash, Cash Equivalents, and Short-term Investments 39.5M USD -50.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 2.58M USD +826%
Assets, Current 28.2M USD -69.3%
Property, Plant and Equipment, Net 651K USD -81.7%
Operating Lease, Right-of-Use Asset 912K USD -31.9%
Other Assets, Noncurrent 538K USD +2.28%
Assets 32.9M USD -66.1%
Accounts Payable, Current 966K USD -49.8%
Employee-related Liabilities, Current 2.66M USD +30.7%
Liabilities, Current 21M USD +84.9%
Operating Lease, Liability, Noncurrent 665K USD -32.8%
Liabilities 67M USD +22.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -291M USD -41.3%
Stockholders' Equity Attributable to Parent -34.1M USD -180%
Liabilities and Equity 32.9M USD -66.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.9M USD -335%
Net Cash Provided by (Used in) Financing Activities -661K USD -102%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 45.7M shares +8.39%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.6M USD -180%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23M USD -72.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.84M USD
Deferred Tax Assets, Valuation Allowance 53.7M USD +35.1%
Deferred Tax Assets, Gross 54.3M USD +35.3%
Operating Lease, Liability 980K USD -24.9%
Depreciation 525K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -67M USD -174%
Lessee, Operating Lease, Liability, to be Paid 1.07M USD -27.3%
Property, Plant and Equipment, Gross 1.92M USD -58.4%
Operating Lease, Liability, Current 315K USD -0.32%
Lessee, Operating Lease, Liability, to be Paid, Year Two 366K USD -1.61%
Lessee, Operating Lease, Liability, to be Paid, Year One 360K USD -7.69%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 89K USD -46.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 247K USD -32.5%
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD +24.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 247K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 621K USD +54.9%
Share-based Payment Arrangement, Expense 8.48M USD -37%
Interest Expense 8.65M USD +35938%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%